SCHEMBL3483555

SCHEMBL3483555

Cc1csc2ccc(O)c(Cl)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.43
ESR1 P03372 6/20 0.36
ESR2 Q92731 6/20 0.36
CYP3A4 P08684 3/20 0.35
MAPK1 P28482 2/20 0.35
HTT P42858 1/20 0.32
ALOX15 P16050 2/20 0.31
PKM P14618 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPT P10636 1/20 0.31
G6PD P11413 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
ALOX12 P18054 1/20 0.31
CYP2C19 P33261 1/20 0.31
CCR6 P51684 1/20 0.31
HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4426300 0.76 CYP2A6 (0.46) CYP2A6
SCHEMBL8655332 0.73 ERN1 (0.46) CYP2A6CYP3A4MAPTHTR2B
SCHEMBL28481670 0.72 TRPA1 (0.41) CYP2A6CYP3A4MAPK1ALOX15PKM
SCHEMBL10859384 0.69 CYP2A6 (0.35) CYP2A6KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL12278096 0.69 CYP2A6 (0.45) CYP2A6
SCHEMBL3483635 0.68 CYP2A6 (0.36) CYP2A6
SCHEMBL2092548 0.68 CYP2A6 (0.41) CYP2A6MAPK1KDM4EALDH1A1CYP1A2
SCHEMBL4429297 0.67 MAPT (0.34) CYP2A6ALOX15ALDH1A1MAPTHPGD
SCHEMBL13764546 0.65 KDR (0.40) CYP2A6HTTPKMMAPTLMNA
SCHEMBL9849381 0.65 CYP3A4 (0.55) ESR1ESR2CYP3A4MAPK1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS CYP2A6 944/4885ESR1 3860/4885ESR2 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.